Rapid cut‐off of blood supply in diseases involving thrombosis is a major cause of morbidity
and mortality worldwide. However, the current thrombolysis strategies offer limited results …

Streptokinase, a 47-kDa protein isolated and secreted by most group A, C and G ß-hemolytic
streptococci, interacts with and activates human protein plasminogen to form an active …

To evaluate the thrombolytic activity of streptokinase-dextran conjugate, a rat model of
arterial thrombosis was used. Briefly, the femoral artery was exposed and a filter paper …

Due to the high morbidity and mortality of cardiovascular diseases, there is an urgent need
for research on antithrombotic strategies. In view of the short half-life, insufficient drug …

Cardiovascular disease is one of the chief factors that cause ischemic stroke, myocardial
infarction, and venous thromboembolism. The elements that speed up thrombosis include …

This study is undertaken to design zinc-stabilized gelatin nano-complexes of tissue-type
plasminogen activator (t-PA) for thrombolytic therapy where the t-PA activity can be …

According to the importance of time in treatment of thrombosis disorders, faster than current
treatments are required. For the first time, this research discloses a novel strategy for rapid …

The formation of a proper fibrin clot is essential during blood coagulation, as abnormal clots
can predispose individuals to bleeding or thrombosis. Despite these concerns, there is …

Thrombolytic therapy by infusion of analogs of tissue plasminogen activator (tPA), other
recombinant-based plasminogen activators (eg, alteplase, reteplase, and tenecteplase) …

For over two decades, our laboratory has explored the use of sterically stabilized micelle
(SSM) as a safe and practical nanocarrier for the delivery of water-insoluble drugs and …